TDC
ABEO icon

Thompson Davis & Co’s Abeona Therapeutics ABEO Stock Holding History

Thompson Davis & Co’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$5K Hold
15
– – 0.01% 559
2018
Q2 		$6K Buy
15
+10
+200% +$4.37K 0.01% 490
2018
Q1 		$2K Buy
+5
New +$1.86K 0.01% 557

Other funds holding ABEO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Thompson Davis & Co's ABEO Position: Q3 2018 in Review

Thompson Davis & Co held its Abeona Therapeutics (ABEO) position steady in Q3 2018 at 15 shares worth $5K. The position accounts for 0.01% of the portfolio, ranked #559.

Thompson Davis & Co first reported a position in ABEO in Q1 2018 and has held it in 3 quarters since. The position peaked at $6K in Q2 2018. 104 funds tracked by Wall St. Rank hold ABEO as of Q3 2018.

  • Thompson Davis & Co held 15 shares of Abeona Therapeutics worth $5K as of Q3 2018.
  • Thompson Davis & Co left its Abeona Therapeutics share count unchanged in Q3 2018.
  • Abeona Therapeutics made up 0.01% of Thompson Davis & Co's portfolio in Q3 2018, its #559 holding.
  • Thompson Davis & Co first reported a position in Abeona Therapeutics in Q1 2018 and has held it in 3 quarters since.
  • Thompson Davis & Co's Abeona Therapeutics position peaked at $6K in Q2 2018.
  • 104 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.